Sugi Predict

Sugi Predict / Targets / CMA1

CMA1

Chymase · P23946 · CMA1 on Sugi Atlas →

66,159 patent compounds predicted against CMA1, 35,983 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL404228 SCHEMBL404228 1.00 19/20
SCHEMBL405161 SCHEMBL405161 0.90 19/20
SCHEMBL407327 SCHEMBL407327 0.78 19/20
SCHEMBL407843 SCHEMBL407843 0.76 19/20
SCHEMBL404213 SCHEMBL404213 0.73 19/20
SCHEMBL406708 SCHEMBL406708 1.00 18/20
SCHEMBL409986 SCHEMBL409986 0.77 18/20
Moxalactam Moxalactam (SCHEMBL49016) 0.68 18/20
Moxalactam Moxalactam (SCHEMBL49017) 0.68 18/20
Moxalactam Moxalactam (SCHEMBL194012) 0.68 18/20
Moxalactam Moxalactam (SCHEMBL194013) 0.68 18/20
Moxalactam Moxalactam (SCHEMBL49015) 0.66 18/20
Flomoxef Flomoxef (SCHEMBL49438) 0.54 18/20
Flomoxef Flomoxef (SCHEMBL65125) 0.53 18/20
SCHEMBL408281 SCHEMBL408281 0.79 17/20
SCHEMBL409547 SCHEMBL409547 0.78 17/20
SCHEMBL409979 SCHEMBL409979 0.75 17/20
SCHEMBL409980 SCHEMBL409980 0.75 17/20
SCHEMBL409742 SCHEMBL409742 0.71 17/20
SCHEMBL409743 SCHEMBL409743 0.71 17/20

Clinical trials — most relevant to CMA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients PHASE2/PHASE3COMPLETED
Allergic Rhinitis, Immunotherapy and Vitamin d PHASE2/PHASE3UNKNOWN
Effects of Anti-TSLP in Patients With Asthma PHASE2COMPLETED
The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose PHASE2COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis PHASE2COMPLETED
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection PHASE1/PHASE2COMPLETED
Serum Basal Tryptase Levels in Healthy Children nanCOMPLETED
Improvement of Foodallergy Diagnostic in Gastrointestinal Tract nanCOMPLETED
Investigation of the Frequency of Hereditary Hyper Alpha-tryptasemia in Patients With Elevated Basal Tryptasemia nanACTIVE_NOT_RECRUITING
Persistence of Sensitization to Contrast Media nanNOT_YET_RECRUITING
Cause of Unexplained Anaphylaxis nanACTIVE_NOT_RECRUITING
Allergy and Immunology Natural History Study nanRECRUITING
GI Alpha-Gal Study nanCOMPLETED
Cause and Natural Course of Pediatric-Onset Mastocytosis nanCOMPLETED
Are Mast Cells Involved in Autoinflammatory Diseases nanNOT_YET_RECRUITING
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing nanCOMPLETED
Dosage of Serum Tryptase Levels in a Population of Premature Newborns to Evaluate Mast Cell Activity nanCOMPLETED
Diagnosis and Allergen Identification of Perioperative Anaphylaxis nanRECRUITING
Role of Esophageal Mast Cell Activation in Noncardiac Chest Pain (NCCP) nanCOMPLETED
The Utility of Serum Tryptase in the Diagnosis of Shrimp- Induced Anaphylaxis nanCOMPLETED
Pathogenesis of Physical Induced Urticarial Syndromes nanCOMPLETED
Mast Cells and Its Proteases in COPD nanUNKNOWN
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
Tryptase Level as a Marker of Complications in Transcatheter Aortic Valve Replacement nanUNKNOWN
Amino Acid Feed Children's Study nanCOMPLETED
Role of Tryptase Levels in Patients With Stable Coronary Artery Disease. nanRECRUITING
Effect of FODMAPs on Mucosal Inflammation in IBS Patients nanUNKNOWN
Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals nanCOMPLETED
Natural History and Genetics of Food Allergy and Related Conditions nanRECRUITING
Prevalence of Allergic Diseases and Atopy in Subjects With Coronary Artery Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CMA1 binder may also engage these)

ProteinNameSimilarity
P56435 — 1.000 P56435 →
P52195 — 0.997 P52195 →
P21842 — 0.995 P21842 →
A7WPL7 — 0.992 A7WPL7 →
P79204 — 0.991 P79204 →
P50341 — 0.991 P50341 →
P21844 — 0.987 P21844 →
P97592 — 0.987 P97592 →
O46683 — 0.986 O46683 →
P20718 — 0.985 P20718 →
KLK3 Prostate-specific antigen 0.984 landscape →
P50339 — 0.984 P50339 →
P80219 — 0.984 P80219 →
P09650 — 0.983 P09650 →
KLK2 Kallikrein-2 0.982 landscape →
GZMB Granzyme B 0.981 landscape →
P21812 — 0.981 P21812 →
Q61096 — 0.981 Q61096 →
P33619 — 0.981 P33619 →
Q6DT45 — 0.979 Q6DT45 →
KLK13 Kallikrein-13 0.979 landscape →
Q9H2R5 — 0.978 Q9H2R5 →
KLK7 Kallikrein-7 0.977 landscape →
P17977 — 0.977 P17977 →
P80931 — 0.977 P80931 →
Q07276 — 0.976 Q07276 →
P50342 — 0.975 P50342 →
Q00356 — 0.975 Q00356 →
PRTN3 Myeloblastin 0.975 landscape →
KLK6 Kallikrein-6 0.975 landscape →